NorthWest Biotherapeutics Inc (NWBO)

[alphapuppy]

My favorite ASCO abstract

ABSTRACT 3096

I really like this abstract because the data demonstrates the success for dendritic cell based immune therapies and they have long follow-up with 10 year survivors. Also the population studied were patients who had multiple metastatic disease. Historically very few of these patients on standard therapy would survive (Maybe a 5yr survival of less than 5% if you were lucky).

The data indicates that the 10 year survival for the dendritic cell immune treatment was 25%. This truly is revolutionary and represents a very significant improvement compared to historical results.

This abstract data really represents an important verification of this new immune therapy. AF.s past statements that these dendritic immune therapies are not "powerful" enough to be viable cancer treatment are not corroborated by this compelling data with a decade of follow-up.

TITLE
"Long-term survival of patients suffering from solid extra-cranial neoplasias after dendritic cell-based cancer immune therapy."

2014 ASCO Annual Meeting
Abstract No:
3096
Attend this session at the
2014 ASCO Annual Meeting!
Session: Developmental Therapeutics - Immunotherapy
Type: General Poster Session
Time: Sunday June 1, 8:00 AM to 11:45 AM
Location: S Hall A2